Investment Intelligence Workstation
Baseline Fabric Moderate risk persona
Active Workspace
Marchi Family
Julio Marchi Long-Term Growth
Canonical Asset

JNJ Johnson & Johnson

Equity Healthcare NYSE USD Active

Latest pricing comes from the newest ingested market-data snapshot when one exists. Portfolio values fall back to the latest transaction price only if snapshot coverage is still missing.

Research Notes Asset Brief Portfolios Watchlists
Held In Portfolios
2
Tracked In Watchlists
1
Personas Referencing
2
Latest Quote Snapshot
$161.26
Baseline seeded snapshots • Captured May 28, 2026 4:05 PM
Held Shares
130
Held Market Value
$20,963.80

Recent Price History

Baseline seeded snapshots • newest first
Latest ingested quote history
5 sessions of snapshot coverage
JNJ close $161.26
Latest close $161.26
Window move +3.5%
Range $153.80 - $163.36
$161.69 $158.55 $155.40 May 22 May 26 May 28
Snapshot history only. This surface does not claim live or streaming market data.
Date Open High Low Close Volume Captured
May 28, 2026 $160.42 $163.36 $158.33 $161.26 10,620,000 May 28, 2026 4:05 PM
May 27, 2026 $159.99 $162.98 $157.67 $160.41 12,240,000 May 27, 2026 4:00 PM
May 26, 2026 $159.39 $161.70 $157.32 $159.39 13,860,000 May 26, 2026 4:00 PM
May 25, 2026 $158.45 $160.51 $155.75 $158.04 9,810,000 May 25, 2026 4:00 PM
May 22, 2026 $156.64 $159.15 $153.80 $155.83 11,430,000 May 22, 2026 4:00 PM

Portfolio Presence

Portfolio Persona Shares Latest Price Mkt Value Gain/Loss
Dividend Aristocrats
Dividend Growth
 Income & Dividends
Julio Marchi
 80 $161.26
Baseline seeded snapshots · May 28, 2026 4:05 PM
$12,900.80 +$420.80
+3.4%
Roth IRA
Index & ETF
 Retirement Fund
Ana Marchi
 50 $161.26
Baseline seeded snapshots · May 28, 2026 4:05 PM
$8,063.00 +$313.00
+4.0%

Watchlist Presence

Dividend Upgrade Candidates
Income & Dividends · Julio Marchi
High Ready
Healthcare stability with dependable dividend profile.
Good fit for income sleeve if valuation cools.
Operating Plan
Edit Plan
Upgrade JNJ only if the defensive income thesis still offsets litigation and pipeline risk; otherwise stand aside.
Below invalidation Mapped to latest ingested price $161.26
$154.00 $175.00
Invalidate $165.00 Entry Low $154.00 Entry High $160.00 Trim $175.00 Current $161.26
Entry: +0.8% above zone Trim: +8.5% to target Risk: +2.3% below invalidation
Review Apr 24, 2026 38 days overdue Cadence 30d
Entry Zone $154.00 - $160.00
Trim $175.00
Invalidate $165.00
Monitor: Review litigation reserve updates, MedTech execution, and dividend coverage before the next decision.
Execution: If the invalidation threshold stays broken, do not average down until the thesis is rewritten.
Added Feb 12, 2025

Catalyst & Event Timeline

baseline records only — no live news feed
Add Event

Upcoming & Active

JNJ Talc Litigation Settlement Watch
Apr 19, 2026 · Ongoing · Seeded baseline
Johnson & Johnson ongoing talc litigation settlement review. Risk monitoring note — no resolution confirmed at this baseline date.
Regulatory Medium Edit

History

Date Type Title Importance Status Source
Apr 15, 2026 Earnings JNJ Q1 2026 Earnings
Johnson & Johnson quarterly results. MedTech segment performance and any talc...
 Medium Completed Seeded baseline Edit